Overview

This trial is active, not recruiting.

Condition incontinence
Treatment urocool (local cooling/hypothermia)
Sponsor Philips Healthcare
Start date May 2013
End date October 2014
Trial size 200 participants
Trial identifier NCT01920035, IT 04-200

Summary

Localized cooling/hypothermia using the UroCool System during robotic-assisted radical prostatectomy (RARP) surgery results in an improved overall return to continence, (defined as not wearing any protective urinary pads), compared with standard of care in men presenting for RARP.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
These patients will have the UroCool device inserted prior to RARP to induce localized cooling/hypothermia of the pelvic region prior to and during RARP surgery.
urocool (local cooling/hypothermia) Cooling group
These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
(No Intervention)
These patients will receive standard of care only for RARP surgery. They will not receive the UroCool investigational device.

Primary Outcomes

Measure
Improved return of overall continence.
time frame: 90 days post RARP

Secondary Outcomes

Measure
Faster return to continence.
time frame: 30, 60 and 90 days

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - Patient is male and a candidate for robotic assisted radical prostatectomy (RARP) for the treatment of prostate cancer - Patient is over eighteen (>18) years of age - Patient reads, understands and speaks English fluently (U.S. Sites only) - Subject understands and agrees to all pre-operative preparation procedures including a "self-administered" fleet enema - Subject understands study procedures, risks of such procedures and is willing to comply with all study procedures - Patient is willing and able to comply with all post-surgical milestones including completing and returning post-surgery follow up questionnaires at specified intervals over a 12 month period - Subject agrees to participate in the study and is willing to sign the written informed consent per the enrolling site's institutional procedure Exclusion Criteria: - Presents with baseline or has a history of urinary incontinence - Rectal or GI pathology deemed unsuitable for placement of the treatment device by the examining physician - Prior extensive pelvic surgery such as low anterior resection, abdominoperineal resection, or proctocolectomy continent stool pouch, or any other extensive abdominopelvic surgery that would render the patient a high-risk for complications as deemed by the surgeon - History of prior treatment of any kind for prostate cancer; e.g. radiation therapy, cryotherapy, high-intensity focused ultrasound (HIFU), hormonal or chemotherapy - Prior intra-operative injuries (for example: rectal injury) - Inadequate hemostasis - Serious concurrent medical condition likely to result in death during the next 12 months. Any other acute or chronic condition which the Investigator believes will unacceptably increase the risk of study participation or interfere with study procedures and assessments. - Active or recent (within 1 month prior to study enrollment) participation in another investigational clinical research study or planned to be enrolled in another study of prostate therapy.

Additional Information

Official title A Randomized, Controlled Study of the Use of Localized Endorectal Cooling Using the UroCool System During Robotic-Assisted Radical Prostatectomy (RARP) to Minimize Trauma and to Provide Earlier Return to Continence
Principal investigator Thomas Ahlering, MD
Description This study will assess the use of an endorectal cooling device, UroCool, to achieve controlled, local hypothermia of the pelvis. The study will evaluate the safety and effectiveness of the device in inducing hypothermia of the neuromuscular tissues impacting continence during RARP. The UroCool system is designed to apply targeted temperature control to the pelvic anatomy during RARP. The pelvis is cooled transrectally via a closed cycle recirculation of chilled sterile saline using a single-use disposable balloon catheter connected via a circulation IV set to a control console that is covered by a current 510(k) and commercially available. The UroCool polymeric catheter is designed to be inserted within the rectal cavity adjacent to the prostate prior to surgery and removed upon completion of surgery. It is used in conjunction with the InnerCool Console which circulates cold saline in a closed loop within the UroCool catheter to allow for therapeutic localized cooling of the prostate gland and surrounding areas during prostate surgery.
Trial information was received from ClinicalTrials.gov and was last updated in November 2014.
Information provided to ClinicalTrials.gov by Philips Healthcare.